Corinne E. Atton

Corinne Atton

Corinne Atton is an accomplished trial attorney with extensive experience representing life sciences- and technology-focused clients in complex and high-stakes intellectual property matters. Corinne's courtroom experience includes bench trials in U.S. district court; trials and motion practice before the Chancery Division (Patents Court) of the High Court of Justice of England and Wales; and appeals before the Court of Appeal (England and Wales). She also represents clients in inter partes review and post-grant review proceedings before the U.S. Patent Trial and Appeal Board.

Corinne also has experience with patent due diligence associated with high-profile acquisitions, and with intellectual property issues in commercial transactions. She focuses on pharmaceuticals, biologics, biotechnology, and medical devices. Corinne has worked on cases concerning DNA sequencing technologies, recombinant polypeptides, enzyme inhibitors, receptor agonists, iron chelators, anti-diabetic drugs, wakefulness-promoting agents, surgical mesh affixing systems, and laser hair removal systems.

Corinne edits, writes for, and manages Venable's BiologicsHQ microsite – a website that provides statistical analyses and timely commentary concerning U.S. patent proceedings relating to FDA-approved biologic drugs. She also regularly publishes and speaks on a wide variety of intellectual property topics and developments.

Corinne formerly practiced as a barrister in England and Wales, where she advised on high-value patent, trademark, and commercial litigation, and international arbitration matters.


Representative Matters

  • Represented Astellas in ANDA litigation and IPR proceedings concerning Myrbetriq® – overactive bladder treatment
  • Represented the Japanese Foundation for Cancer Research before the federal circuit on a question concerning review of patent interference decisions
  • Represented Novartis in ANDA litigation and IPR proceedings concerning Zortress® (everolimus) – prophylaxis of kidney and liver transplant rejection
  • Represented Novartis in ANDA litigations concerning Exjade ® (deferasirox) – a pharmaceutical metal chelator
  • Represented GSK in ANDA litigations concerning Avodart® (dutasteride) and Jalyn® (dutasteride and tamsulosin) – benign prostatic hyperplasia treatment
  • Represented Spectrum Brands in medical device litigation – light hair removal systems
  • Performed due diligence associated with Mitsubishi Tanabe Pharma's acquisition of Neuroderm (Rehovot, Israel)

Representative Clients

  • Novartis
  • Gilead
  • Astellas Pharma
  • Mitsubishi Tanabe Pharma




  • LL.M. Columbia Law School 2008
    • Harlan Fiske Stone Scholar
  • B.V.C. BPP Law School 2002
    • Cassel Scholarship from Lincoln's Inn
  • Pg DL BPP Law School 2001
    • Thomas More Memorial and Hardwicke Scholarships from Lincoln's Inn
  • B.S. with honors University College London 2000

Bar Admissions

  • New York
  • England and Wales (Barrister)

Court Admissions

  • U.S. Supreme Court
  • U.S. Court of Appeals for the Federal Circuit
  • U.S. District Court for the Southern District of New York
  • U.S. District Court for the Eastern District of New York


  • Included in Who's Who Legal Life Sciences: Patent Litigation, 2017 - 2020
  • Listed as a "Rising Star" in Intellectual Property Litigation, Super Lawyers: New York Metro Edition, 2017 - 2019